AstraZeneca plc (NYSE:AZN) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $48.83 and last traded at $48.83, with a volume of 7843500 shares changing hands. The stock had previously closed at $43.27.

Several analysts have recently issued reports on the stock. DZ Bank lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Tuesday, September 3rd. ValuEngine lowered shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Argus lifted their target price on shares of AstraZeneca to $50.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Four investment analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $45.96.

The company’s 50-day moving average price is $44.30 and its 200-day moving average price is $41.16. The firm has a market cap of $113.53 billion, a price-to-earnings ratio of 24.88, a price-to-earnings-growth ratio of 1.44 and a beta of 0.49. The company has a quick ratio of 0.75, a current ratio of 0.95 and a debt-to-equity ratio of 1.19.

AstraZeneca (NYSE:AZN) last announced its earnings results on Thursday, July 25th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.30 by $0.43. AstraZeneca had a net margin of 9.38% and a return on equity of 35.83%. The business had revenue of $5.72 billion for the quarter, compared to analyst estimates of $5.57 billion. During the same quarter last year, the business earned $0.69 earnings per share. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. Analysts predict that AstraZeneca plc will post 1.81 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Manchester Financial Inc. acquired a new position in AstraZeneca during the second quarter worth about $25,000. Oakworth Capital Inc. boosted its position in AstraZeneca by 141.0% during the second quarter. Oakworth Capital Inc. now owns 964 shares of the company’s stock worth $40,000 after acquiring an additional 564 shares during the last quarter. San Francisco Sentry Investment Group CA boosted its position in AstraZeneca by 37.6% during the second quarter. San Francisco Sentry Investment Group CA now owns 967 shares of the company’s stock worth $40,000 after acquiring an additional 264 shares during the last quarter. Winslow Evans & Crocker Inc. boosted its position in AstraZeneca by 58.6% during the second quarter. Winslow Evans & Crocker Inc. now owns 1,050 shares of the company’s stock worth $44,000 after acquiring an additional 388 shares during the last quarter. Finally, Legacy Advisors LLC acquired a new position in AstraZeneca during the second quarter worth about $48,000. Hedge funds and other institutional investors own 17.68% of the company’s stock.

AstraZeneca Company Profile (NYSE:AZN)

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Recommended Story: S&P 500 Index

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.